Pakhuri Mehta

Pakhuri Mehta

Active Director Director DIN 09249462
DIN 09249462 First appointment Jul 2021 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2021
Shareholding value •••• Premium profile

About Pakhuri Mehta

Data last updated:

Pakhuri Mehta is a Director at Ucardix Pharmaceuticals Private Limited (since 2021). The company operates in Pharma. Ucardix Pharmaceuticals Private Limited reported revenue of ₹7.56 Cr (FY 2025).

DIN 09249462
Primary Designation Director
Industry Pharma
First Appointment 22 Jul 2021
Oldest Company Age 5 yrs
Largest company Ucardix Pharmaceuticals Private Limited · ₹7.56 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director22 Jul 20212021₹7.56 Cr (FY 2025)Active

Board colleagues of Pakhuri Mehta

Directorship timeline

Open interactive timeline →
Ucardix Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Pakhuri Mehta

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Pakhuri Mehta

Pakhuri Mehta currently holds 1 directorship: Ucardix Pharmaceuticals Private Limited (Director, since 22 Jul 2021, revenue ₹7.56 Cr (FY 2025)).

Pakhuri Mehta was first appointed on 22 Jul 2021 as Director at Ucardix Pharmaceuticals Private Limited.

The current boards of Pakhuri Mehta's companies include Maya Sharma (Ucardix Pharmaceuticals Private Limited), Poonam Sharma (Ucardix Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available